EDIT News and Press, Editas Medicine Inc. From 09/02/25

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 ...

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce t...

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in Septe...

2025-08-15 08:15:10 ET H.C. Wainwright analyst issues BUY recommendation for EDIT on August 15, 2025 10:14AM ET. The previous analyst recommendation was Buy. EDIT was trading at $2.96 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2025-08-15 07:50:43 ET Gene-editing company Editas Medicine (NASDAQ: EDIT) was something of an unexpected star on the stock exchange as the trading week came to a close. The small biotech's share price was up by a robust 34% week to date as of early Friday morning, according to data...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

2025-08-12 16:46:57 ET More on Editas Medicine Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible Gene editors steady despite latest leadership shake-up at FDA RFK Jr. looks to fast track rare disease drug approvals (updated) Seeking Alpha&...

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas ...

2025-08-12 10:00:00 ET Editas Medicine (NASDAQ: EDIT) , a small-cap biotech company, is up by 81% since January. But zooming out gives us a completely different picture. The gene-editing specialist has significantly lagged the market over the past year -- and since the turn of the d...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...